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letter to editorEarly T cell
precursor lymphoid blast
crisis of chronic
myeloid leukemia – A novel
transformation
Chronic myeloid leukemia
(CML) is a myeloproliferative dis-
order with an overall incidence of
0.6 to 2 cases per 100,000 per year.1
The breakpoint cluster region–
Abelson (BCR–ABL) fusion pro-
tein with constitutive tyrosine
kinase activity drives uncontrolled
cell proliferation leading to accu-
mulation of myeloid precursors
and mature cells in the peripheral
blood, bone marrow and extramed-
ullary sites.2,3 Tyrosine kinase
inhibitors (TKI) have dramatically
improved the prognosis of CML,
with an estimated median survival
of 25 to 30 years.4 Disease progres-
sion to accelerated phase or blast
crisis remains the main cause of
mortality. The incidence of myeloid
blast crisis is around 50% compared
to around 25% each for lymphoid
blast crisis and undifferentiated
phenotypes.5,6 Almost 95% of
lymphoid blast crises are of B cellTable 1. Blood investigations at presentation.
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of an early T cell precursor (ETP)
lymphoid blast crisis of CML in
an adult patient. ETP acute lym-
phoblastic leukemia (ALL) reﬂects
a distinct subset of ALL with mye-
loid cell phenotype7 and poor out-
comes.8 Standard ALL therapies
are inadequate in providing good
overall survival rates. Allogeneic
stem cell transplantation in ﬁrst
remission provides the best results
but there is a need for tailored ther-
apy incorporating myeloid directed
cytotoxic drugs.8
A 27-year-old man with no sig-
niﬁcant history presented with a
two-month history of abdominal
distension and loss of appetite.
Clinical examination revealed mul-
tiple cervical, axillary, and inguinal
lymphadenopathies along with
massive splenomegaly of 18 cm.
Laboratory parameters at diagnosis
are given in Table 1. Fluorescence
in situ hybridisation (FISH) was
100% positive for BCR–ABL
fusion product. Cervical lymph
node biopsy was consistent with
T cell lymphoblastic lymphoma.
A bone marrow evaluation showed9.1 gm/dl Creatinine
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2692 IU/ml Uric acida solidly cellular aspirate with 44%
blasts that were periodic acid Schiff
and Sudan black negative. Flow
cytometry on the bone marrow
sample revealed an early T cell pre-
cursor phenotype (Figure 1,
Table 2). Conventional karyotyp-
ing showed t(9, 22) in all 20 meta-
phases. The clinical presentation,
basophilia on peripheral blood
and a 100% FISH positivity for
BCR–ABL pointed more toward
a CML with blast crisis than a de
novo T cell ALL. Bone marrow
trephine was consistent with
CML in blast transformation. Cen-
tral nervous system (CNS) involve-
ment was ruled out by normal
cerebrospinal ﬂuid (CSF) analysis
at diagnosis and there was no medi-
astinal mass or testicular involve-
ment. The patient was started on
the Berlin–Frankfurt–Munster
(BFM) ALL adult protocol, and
there was good response to steroids
on day 8. Imatinib was also started
at a dose of 400 mg once daily. Fol-
lowing Phase I induction chemo-
therapy consisting of vincristine,
daunorubicin, l-asparaginase and
prednisolone along with imatinib,1.4 mg/dl (Ref Normal 0.7–1.2 mg/dl)
st:
0.9 mg%
0.3 mg%
8.8 g%
4.4 g%
20 U/L
18 U/L
. 107 U/L
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Figure 1. Flow cytometric analysis of the patient. A dot plot of CD45 vs side scatter gating showing the leukemic blasts. The cell marker profile
shows a distinct immature immunophenotype characterised by lack of CD1a and CD8 expression and weak CD5 expression of less than 75% on
38% of lymphoblasts. The gated abnormal population also shows the expression of one or more myeloid and stem cell markers such as CD33,
CD13, HLADR and CD34, which fulfill the criteria for ETP-ALL. The lymphoblasts were negative for surface CD3, CD4 and CD117, but they express
CD7, CD10, CD2 and cytoplasmic CD3.
Table 2. Comparison of bone marrow flow cytometric analysis of our patient with immunophenotypic criteria for diagnosis of ETP ALL.
Bone marrow flow cytometry of the patient Flow cytometry based diagnostic criteria for ETP-ALL8
Markers Expression
CD1a – 2% CD 13–97.3% CD1a <5% cells
CD4–9% CD33–93.3% CD8 <5% cells
CD5 (dim) – 72% CD34–82.2% CD5 <75% cells (weak expression)
CD7–90.3% HLADR–67.1% CD13, CD33, CD34, >25% cells positive for one or more
CD8–0.9% Cyto CD3–67.4% C11b, CD65, CD117
HLADR
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letter to editorhis bone marrow was found to be
in remission. However, there was
evidence of meningeal disease as
CSF analysis revealed the presenceof abnormal cells on cytospin. The
patient was started on CNS direc-
ted therapy and dasatinib 100 mg
once daily. Following Phase IIHeminduction with cyclophosphamide
and cytosine, bone marrow showed
6.5% blasts. The patient did not
have a human leukocyte antigenatol Oncol Stem Cell Ther 8(1) First Quarter 2015
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(HLA) identical sibling and
resources were poor for a matched
unrelated donor transplant. He
was given four more doses of weekly
vincristine and prednisolone along
with dasatinib, but a repeat bone
marrow revealed mildly hypercellular
marrow with 8% blasts. In view of
the refractory disease, he was started
on BFM 85 Relapse protocol. Fol-
lowing the ﬁrst cycle, he continued
to have blasts on the peripheral
smear. Due to inadequate ﬁnances
for further intensive chemotherapy,
the patient opted for palliative che-
motherapy. He was started on vin-
cristine, dexamethasone-based therapy
and was continued on dasatinib. His
disease progressed and he remained
pancytopenic with a progressive
increase in blasts. The family subse-
quently discontinued therapy, and he
succumbedtosevereneutropenic sepsis
after one year of blast transformation.
CML is caused by the BCR–
ABL fusion gene, leading most
commonly to the p210BCR/ABL
oncoprotein with very high levels
of tyrosine kinase activity. The dis-
ease progresses through a chronic
phase, an accelerated phase with
accumulation of more premature
cells and a terminal blast transfor-
mation that behaves like acute leu-
kemias, and requires therapy on
similar lines.3 With the advent of
TKIs, progression to accelerated
phase and blast crisis has decreased
to around 1% per year now com-
pared to 20% in the pre-imatinib
era.4,9 Imatinib resistance poses a
challenge to disease control. Newer
generation TKIs circumvent imati-
nib resistance due to many but not
all TKI site mutations,10 and pro-
vide options for disease control in
imatinib resistant patients. Despite
such therapies, disease progression
occurs and brings down overall sur-
vival signiﬁcantly.
Blast crisis in CML depicts a
clonal evolution of abnormal cells
that have gathered during theHematol Oncol Stem Cell Ther 8(1) First Quarter 2015chronic phase.10 The biology of
blast crisis remains elusive, but sev-
eral mechanisms have been impli-
cated. BCR–ABL related genomic
instability seems to play a major
role which increases in proportion
to BCR–ABL activity.11,12 The
leukemic stem cells are inherently
insensitive to the TKIs, and proba-
bly evade the TKI induced cell pro-
liferation.11 Common additional
cytogenic abnormalities include
double Philadelphia chromosome
positivity, trisomy 8 and isochro-
mosome 17, whereas inactivation
of p53 through mutation, or func-
tional inactivation is the most com-
mon molecular abnormality.3,13
Lymphoid blast crisis consti-
tutes around 25% of blast transfor-
mation in CML.5,6 Most lymphoid
blast crises are of B cell type with
very few reported T cell pheno-
types.6 Sudden onset blast crisis is,
however, more common with lym-
phoid than myeloid blast transfor-
mation.14 ETP-ALL in general
reﬂects a distinct subset of ALL,
and is associated with a poor prog-
nosis with convention ALL thera-
pies.8 This is a rare case of a CML
presenting in ETP lymphoid blast
crisis in an adult. The only other
reported case was in a pediatric
CML patient who was diagnosed
as transformed to ETP lymphoid
blast crisis on the basis of immuno-
histochemistry on the lymph
node.15 The diagnosis of ETP
ALL is made on ﬂow cytometry
by the presence ofmyeloid and stem
cell markers together with T cell
markers8,16 (Table 2). It possesses
a genetic signature that is closer to
myeloid cell lines and haematopoi-
etic stem cells.7,17 Therapy for
ETP ALL remains challenging,
with inclusion of myeloid directing
chemotherapeutic agents hoping
to show some beneﬁt. There are
no clear cut guidelines however
and it remains a ﬁeld to be explored.
Allogeneic stem cell transplantationfrom a suitable donor in ﬁrst remis-
sion after inducing a chronic phase
provides the best results in a blast
crisis of CML.18 However, the
absence of a suitable donor remains
the biggest hindrance. The combi-
nation of CML blast transforma-
tion to ETP ALL type reﬂects a
very aggressive tumor subtype with
a distinct biology that warrants
aggressive and tailored therapy,
including myeloid directed cyto-
toxic agents with traditional ALL
induction therapies followed by
allogeneic stem cell transplantation.CONFLICT OF INTEREST
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